Full Press Release Details
Treated for Erectile Dysfunction Utilizing Company's Patented CaverStem Stem Cell Procedure with Significant
updates and plans for second half of 2019.
Phoenix, AZ, June 20, 2019
- Creative Medical Technology Holdings, Inc. (OTCQB: CELZ), a leading commercial stage
biotechnology company focused on Urology, Orthopedics and Neurology using stem cell treatments, today announced business updates
and plans for remainder of 2019.
Recent Business Highlights
Ahead (H2 2019 Plans)
"We are at an inflection
point in our efforts to establish Creative Medical Technology Holdings, Inc. as the pre-eminent leader in unlocking the full potential
of stem cells for medical breakthroughs in the areas of Urology, Orthopedics and Neurology", said Timothy Warbington, President
and CEO of Creative Medical Technology Holdings Inc. "We are thrilled by the support of the medical community for our leading
CaverStem procedure and energized by the success stories that are pouring in from around the world from men whose lives have
been drastically improved as a direct result of our products. We remain steadfast in our commitment to accelerate adoption of
CaverStem and utilize our existing relationships with HCPs to introduce FemCelz to help the growing number of women
that experience sexual dysfunction."
About Erectile Dysfunction
Erectile dysfunction (ED) is
characterized by the lack of ability to achieve and maintain penile erection for intercourse. Methods used to quantify ED
include the Erectile Function Visual Analog Scale (EF-VAS) and the International Index of Erectile Function (IIEF-5), however
clinically it is primarily diagnosed based on symptomology. In our aging society, ED is becoming an increasing problem.
According to one study 39% of men at age 40 experience symptoms of ED, whereas by age 70 the incidence rises to 67%. In this latter
age group, it is believed that 50-85% of ED cases are associated with hypertension, diabetes, cardiovascular disease and dyslipidemia.
Overall, it is estimated that 10-30 million Americans suffer from this condition.
Creative Medical Technology Holdings
Creative Medical Technology Holdings,
Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and
orthopedics and trades on the OTCQB under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com.
Forward Looking Statements
Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may
contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical
trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions
and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated
in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities
and Exchange Commission and available on the Commission's website at www.sec.gov.
Creativemedicaltechnology.com
Timothy Warbington, CEO